33.51
price down icon1.06%   -0.36
after-market Dopo l'orario di chiusura: 33.51
loading
Precedente Chiudi:
$33.87
Aprire:
$33.68
Volume 24 ore:
1.30M
Relative Volume:
0.46
Capitalizzazione di mercato:
$6.63B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-13.90
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
-3.85%
1M Prestazione:
-3.62%
6M Prestazione:
+33.19%
1 anno Prestazione:
+35.45%
Intervallo 1D:
Value
$33.21
$34.29
Intervallo di 1 settimana:
Value
$33.10
$35.16
Portata 52W:
Value
$21.62
$39.47

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Nome
Bridgebio Pharma Inc
Name
Telefono
(650) 391-9740
Name
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Name
Dipendente
730
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
BBIO's Discussions on Twitter

Confronta BBIO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BBIO
Bridgebio Pharma Inc
33.51 6.63B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-31 Iniziato Redburn Atlantic Buy
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-10-03 Iniziato Oppenheimer Perform
2024-09-04 Iniziato Piper Sandler Overweight
2024-03-21 Ripresa Raymond James Outperform
2024-01-31 Iniziato BMO Capital Markets Market Perform
2023-12-08 Iniziato Wells Fargo Overweight
2023-11-07 Iniziato Citigroup Buy
2023-10-24 Iniziato Cantor Fitzgerald Overweight
2023-07-18 Downgrade Jefferies Buy → Hold
2023-04-19 Iniziato Evercore ISI Outperform
2023-02-06 Iniziato Cowen Outperform
2021-12-27 Reiterato Mizuho Buy
2021-12-27 Reiterato SVB Leerink Outperform
2021-09-10 Aggiornamento BofA Securities Neutral → Buy
2021-05-21 Iniziato UBS Buy
2021-03-22 Reiterato Goldman Buy
2021-02-22 Ripresa JP Morgan Overweight
2021-02-09 Ripresa Goldman Buy
2021-01-11 Reiterato H.C. Wainwright Buy
2020-12-10 Reiterato H.C. Wainwright Buy
2020-06-25 Iniziato BofA/Merrill Neutral
2020-05-19 Iniziato BTIG Research Buy
2020-04-13 Iniziato H.C. Wainwright Buy
2020-02-19 Iniziato Mizuho Buy
2019-07-26 Iniziato Raymond James Outperform
2019-07-22 Iniziato BMO Capital Markets Outperform
2019-07-22 Iniziato Goldman Buy
2019-07-22 Iniziato JP Morgan Overweight
2019-07-22 Iniziato Jefferies Buy
2019-07-22 Iniziato Piper Jaffray Overweight
2019-07-22 Iniziato SVB Leerink Outperform
Mostra tutto

Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie

pulisher
Apr 16, 2025

BridgeBio Pharma director Ellis sells $350,000 in stock By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

BridgeBio Pharma director Ellis sells $350,000 in stock - Investing.com Australia

Apr 16, 2025
pulisher
Apr 15, 2025

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool

Apr 15, 2025
pulisher
Apr 15, 2025

BridgeBio (BBIO) Receives Increased Price Target from H.C. Wainw - GuruFocus

Apr 15, 2025
pulisher
Apr 12, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BBIO Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

BridgeBio Pharma (BBIO) Sees Promising Growth Amid Market Volati - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

BridgeBio Expands Team: Strategic Equity Grants Awarded to 20 New Hires - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Praxis Precision Medicines (PRAX) - The Globe and Mail

Apr 10, 2025
pulisher
Apr 04, 2025

BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock By Investing.com - Investing.com Canada

Apr 04, 2025
pulisher
Apr 03, 2025

BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Redburn Atlantic Initiates Coverage of BridgeBio Pharma (MUN:2CL) with Buy Recommendation - Nasdaq

Apr 03, 2025
pulisher
Apr 01, 2025

Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire

Apr 01, 2025
pulisher
Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat

Mar 31, 2025
pulisher
Mar 29, 2025

Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus

Mar 29, 2025
pulisher
Mar 29, 2025

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025
pulisher
Mar 29, 2025

(BBIO) Technical Data - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 29, 2025

Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN

Mar 29, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio’s Beyonttra approved in Japan - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Beyonttra(TM) (Acoramidis), The First Near-Complete TTR Stabilizer (>=90%), Approved in Japan To Treat ATTR-CM - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Japan approves new ATTR-CM treatment Beyonttra - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing Heart Disease Drug Beyonttra Achieves 42% Mortality Reduction in Japan - Stock Titan

Mar 27, 2025
pulisher
Mar 24, 2025

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

BridgeBio Pharma to Present Cardiovascular Outcomes Data from ATTRibute-CM Study at ACC Annual Scientific Sessions 2025 - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Achondroplasia Treatment Market Size in 7MM is expected to grow - openPR

Mar 24, 2025
pulisher
Mar 23, 2025

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug - MSN

Mar 23, 2025
pulisher
Mar 22, 2025

BridgeBio Pharma Inc (BBIO) Announces Equity Grants to New Employees - GuruFocus.com

Mar 22, 2025
pulisher
Mar 21, 2025

Bridgebio Pharma reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:05 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma - MedCity News

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam prices heart drug at premium to rivals - BioPharma Dive

Mar 21, 2025
pulisher
Mar 21, 2025

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

NYSE Content advisory: Pre-Market update + Stocks try for weekly gains - The Globe and Mail

Mar 21, 2025
pulisher
Mar 21, 2025

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion’s board - Endpoints News

Mar 21, 2025
pulisher
Mar 20, 2025

Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval - News & Insights

Mar 20, 2025

Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):